Form 8-K ARQULE INC For: Mar 07
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Needham & Company Reiterates Bullish View on ArQule (ARQL) as Partial Response Seen in C481S Mutant Patient with ARQ-531
March 7, 2019 1:44 PM ESTNeedham & Company analyst Chad Messer reiterated a Buy rating and $7 price target on ArQule (NASDAQ: ARQL) after a partial response was observed in ibrutinib refractory C481S mutant patient with ARQ-531.
"ArQule reported that the first patient treated in the current 7th... More
